Fetal Hematogenous Routing of a Donor Hematopoietic Stem Cell Line in a Healthy Syngeneic Model of Transamniotic Stem Cell Therapy

Abstract Background/Purpose In utero administration of hematopoietic stem cells (HSCs) has a variety of actual or potential clinical applications but is hindered by invasive, morbid administration techniques. We sought to determine whether donor HSCs could reach the fetal circulation after simple intra-amniotic delivery in a syngeneic rat model of transamniotic stem cell therapy (TRASCET). Methods Pregnant Lewis rat dams underwent volume-matched intra-amniotic injections in all fetuses (n=90) on gestational day 17 (E17; term=E21-22) of a suspension of commercially available syngeneic Lewis rat HSCs labeled with luciferase (n=37 fetuses) or an acellular suspension of recombinant luciferase (n=53). HSC phenotype was confirmed by flow cytometry. Fetuses were euthanized at term for screening of luciferase activity at select anatomical sites. Statistical comparisons were by Fisher's exact test. Results Among survivors (47/90; 52.2%), donor HSCs were identified selectively in the placenta (p=0.003), umbilical cord (p Conclusions Donor hematopoietic stem cells undergo hematogenous routing and can reach the fetal bone marrow, after simple intra-amniotic delivery in a syngeneic rat model. Transamniotic stem cell therapy may become a practicable, minimally invasive strategy for the prenatal administration of these cells.